Moreover, although dMMR is considered a more reliable and robust biomarker than PD-L1, it is not without limitations, and it must be acknowledged that approximately 20% of patients with dMMR tumours exhibit primary resistance to immunotherapy. This evidence concerns the gene CD274 and neoplasm.